Global Closed-Loop Insulin Delivery Systems Market - 2025-2033
Global Closed-Loop Insulin Delivery Systems Market – Market Insights
The global closed-loop insulin delivery systems market reached US$ 35.56 billion in 2024 and is expected to reach US$ 69.01 billion by 2033, growing at a CAGR of 7.7% during the forecast period 2025-2033.
The global closed-loop insulin delivery systems market is driven by various factors like, technological advancements in diabetes management, rising prevalence in diabetes and others, whereas also the market has significant challenges like, limited patient awareness and adoption, technical issues which hinders the market during the forecast period.
Global Closed-Loop Insulin Delivery Systems Market Dynamics - Drivers & Restraints
Technological Advancements in Diabetes Management are Driving the Market Growth
The global closed-loop insulin delivery systems market observed growth as technological advances in the field of diabetes management relations. Continuous glucose monitoring sensors and insulin pumps improved hybrid closed-loop systems in terms of accuracy, reliability, and user-friendliness. These systems locally and automatically adjust the insulin delivery to the blood glucose levels detected and so minimize human interference. The better the system works, the more it appeals to the patient and the healthcare provider, depending on its newly integrated features, such as smartphone compatibility and Bluetooth connectivity, the device adoption rate of which is fast in the developed regions.
For instance, in March 2025, Tandem Diabetes Care, Inc., an insulin delivery and diabetes technology company, announced the launch of Control-IQ+ technology in the United States, which is the next generation of the company's technologically advanced hybrid closed-loop algorithm. Control-IQ+, which operates with both t: slim X2 insulin pump and Tandem Mobi System, will now be provided to people with type 1 diabetes 2 years and older, as well as adults affected with type 2 diabetes. These new pumps come pre-loaded with the software and are already shipping out to new customers, whereas all eligible Tandem customers with an in-warranty system will gain access to the new features via a free remote software update.
Limited Patient Awareness and Adoption Restraining the Market Growth
The global market for closed-loop systems for insulin delivery faces limited patient awareness and adoption as major challenges. Especially in areas endowed with lower levels of healthcare literacy, patients may never have learned the full benefit of these systems.
The realization that these systems were very technically complicated, or are at least perceived as such, along with doubts about their reliability and the need to oversee their operation constantly, may have generated doubt in their minds regarding whether to accept new technologies into their lives. There is also the potential that patients' worries relating to the learning curve of these modern systems may have been a deterrent in their switching from old-school traditional treatment methods, thus slowing down their adoption rate at large.
Global Closed-Loop Insulin Delivery Systems Market - Segment Analysis
The global closed-loop insulin delivery systems market is segmented based on device type, patient demographics, control mechanisms, end-user, and region.
Device Type:
The hybrid closed-loop systems segment is expected to hold 56.1% of the closed-loop insulin delivery systems market
Hybrid closed-loop systems (HCL systems) represent the most advanced insulin-delivery technology to date in that they provide an automation for insulin dosing when coupled with continuous glucose monitoring (CGM). Since insulin delivery is compensated for measured blood glucose levels, patients can add additional doses manually. This mode of delivery gives the most exact control of a patient's blood sugar with the least amount of input from the patient, and hence improves the quality of life for the diabetic patient.
Hybrid closed-loop systems, in general, are considered suitable for children and adults who have type 1 diabetes, though this will greatly depend on the licensing restrictions placed on each system. For those having insulin-dependent type 2 diabetes, systems are not available yet under the NHS, but we've financed research in this sector with the aim that such support shall bridge the existing gap. Our support undoubtedly extends to the entire area of artificial pancreas research.
Hybrids are mainly in looming since the skyrocketing population of Type 1 diabetes cases in developed regions leads to an ever-increasing demand for effective tools assisting in diabetes management. These types of systems have so many pros versus conventional insulin delivery methods: better glycemic control, less burden on the patient. Advances in technologies of CGMs and insulin pumps are making these systems more dependable and easier to access. Public awareness of such devices and reimbursement options is also accelerating the widespread acceptance. Convenience and treatment that is truly customized are increasing favorably for market growth for hybrid closed-loop systems.
For instance, in 2023, ViCentra B.V., the company behind Kaleido, brought forth the Hybrid Closed Loop system for automated insulin delivery. This delivery is granted by the DBLG1 algorithm, which takes input from the Dexcom G6 Continuous Glucose Monitoring (CGM) sensor.
Global Closed-Loop Insulin Delivery Systems Market - Geographical Analysis
North America is expected to 42.1% in the closed-loop insulin delivery systems market
The North America closed-loop insulin delivery systems market is growing on account of the presence of an advanced healthcare infrastructure, a high incidence of Type 1 diabetes, the reimbursement framework, increasing awareness, and patient-education programs for diabetes self-care, plus preference for home-based healthcare, especially after the pandemic. Such a reimbursement framework in the region encourages patients to buy closed-loop systems offered at exorbitant prices, whereas the presence of prominent market players wondrously enhances technological advancement and product availability. Regulatory support, patient educational programs, and preference for home-based healthcare set the path for growth in the market.
For instance, in April 2025, Insulet Corporation announced that sales of Omnipod 5 have begun in Canada. Omnipod 5 is the first tubeless, waterproof Automated Insulin Delivery (AID) System approved in Canada for use by individuals two years of age and older with type 1 diabetes.
Asia-Pacific is expected to 24.5% in the closed-loop insulin delivery systems market
The Asia-Pacific region's closed-loop insulin delivery systems market is experiencing substantial development, which is primarily due to the increasing prevalence of diabetes, particularly in countries like China, India, and Japan. The significant increase in the number of diabetics has resulted in a compelling need for advanced and efficient insulin management solutions. Government initiatives and supportive healthcare policies, such as subsidized access to insulin devices in countries such as Australia, are further driving the adoption of these systems.
Additionally, the deployment and accessibility of these inventive diabetes management tools throughout the region are being facilitated by the ongoing development of healthcare infrastructure in emerging economies.
For instance, according to the International Diabetes Federation, Japan, among the 20 IDF Western Pacific region countries, is facing a significant increase in diabetes prevalence, with an estimated 260 million people affected by the disease by 2045.
Global Closed-Loop Insulin Delivery Systems Market – Major Manufacturers
The major global players in the closed-loop insulin delivery systems market include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Bigfoot Biomedical, Roche Diabetes Care, MicroTech Medical, Medtrum Technologies, Senseonics, and EOFlow, among others.
Global Closed-Loop Insulin Delivery Systems Market - Industry Trends
Target Audience 2024
The global closed-loop insulin delivery systems market reached US$ 35.56 billion in 2024 and is expected to reach US$ 69.01 billion by 2033, growing at a CAGR of 7.7% during the forecast period 2025-2033.
The global closed-loop insulin delivery systems market is driven by various factors like, technological advancements in diabetes management, rising prevalence in diabetes and others, whereas also the market has significant challenges like, limited patient awareness and adoption, technical issues which hinders the market during the forecast period.
Global Closed-Loop Insulin Delivery Systems Market Dynamics - Drivers & Restraints
Technological Advancements in Diabetes Management are Driving the Market Growth
The global closed-loop insulin delivery systems market observed growth as technological advances in the field of diabetes management relations. Continuous glucose monitoring sensors and insulin pumps improved hybrid closed-loop systems in terms of accuracy, reliability, and user-friendliness. These systems locally and automatically adjust the insulin delivery to the blood glucose levels detected and so minimize human interference. The better the system works, the more it appeals to the patient and the healthcare provider, depending on its newly integrated features, such as smartphone compatibility and Bluetooth connectivity, the device adoption rate of which is fast in the developed regions.
For instance, in March 2025, Tandem Diabetes Care, Inc., an insulin delivery and diabetes technology company, announced the launch of Control-IQ+ technology in the United States, which is the next generation of the company's technologically advanced hybrid closed-loop algorithm. Control-IQ+, which operates with both t: slim X2 insulin pump and Tandem Mobi System, will now be provided to people with type 1 diabetes 2 years and older, as well as adults affected with type 2 diabetes. These new pumps come pre-loaded with the software and are already shipping out to new customers, whereas all eligible Tandem customers with an in-warranty system will gain access to the new features via a free remote software update.
Limited Patient Awareness and Adoption Restraining the Market Growth
The global market for closed-loop systems for insulin delivery faces limited patient awareness and adoption as major challenges. Especially in areas endowed with lower levels of healthcare literacy, patients may never have learned the full benefit of these systems.
The realization that these systems were very technically complicated, or are at least perceived as such, along with doubts about their reliability and the need to oversee their operation constantly, may have generated doubt in their minds regarding whether to accept new technologies into their lives. There is also the potential that patients' worries relating to the learning curve of these modern systems may have been a deterrent in their switching from old-school traditional treatment methods, thus slowing down their adoption rate at large.
Global Closed-Loop Insulin Delivery Systems Market - Segment Analysis
The global closed-loop insulin delivery systems market is segmented based on device type, patient demographics, control mechanisms, end-user, and region.
Device Type:
The hybrid closed-loop systems segment is expected to hold 56.1% of the closed-loop insulin delivery systems market
Hybrid closed-loop systems (HCL systems) represent the most advanced insulin-delivery technology to date in that they provide an automation for insulin dosing when coupled with continuous glucose monitoring (CGM). Since insulin delivery is compensated for measured blood glucose levels, patients can add additional doses manually. This mode of delivery gives the most exact control of a patient's blood sugar with the least amount of input from the patient, and hence improves the quality of life for the diabetic patient.
Hybrid closed-loop systems, in general, are considered suitable for children and adults who have type 1 diabetes, though this will greatly depend on the licensing restrictions placed on each system. For those having insulin-dependent type 2 diabetes, systems are not available yet under the NHS, but we've financed research in this sector with the aim that such support shall bridge the existing gap. Our support undoubtedly extends to the entire area of artificial pancreas research.
Hybrids are mainly in looming since the skyrocketing population of Type 1 diabetes cases in developed regions leads to an ever-increasing demand for effective tools assisting in diabetes management. These types of systems have so many pros versus conventional insulin delivery methods: better glycemic control, less burden on the patient. Advances in technologies of CGMs and insulin pumps are making these systems more dependable and easier to access. Public awareness of such devices and reimbursement options is also accelerating the widespread acceptance. Convenience and treatment that is truly customized are increasing favorably for market growth for hybrid closed-loop systems.
For instance, in 2023, ViCentra B.V., the company behind Kaleido, brought forth the Hybrid Closed Loop system for automated insulin delivery. This delivery is granted by the DBLG1 algorithm, which takes input from the Dexcom G6 Continuous Glucose Monitoring (CGM) sensor.
Global Closed-Loop Insulin Delivery Systems Market - Geographical Analysis
North America is expected to 42.1% in the closed-loop insulin delivery systems market
The North America closed-loop insulin delivery systems market is growing on account of the presence of an advanced healthcare infrastructure, a high incidence of Type 1 diabetes, the reimbursement framework, increasing awareness, and patient-education programs for diabetes self-care, plus preference for home-based healthcare, especially after the pandemic. Such a reimbursement framework in the region encourages patients to buy closed-loop systems offered at exorbitant prices, whereas the presence of prominent market players wondrously enhances technological advancement and product availability. Regulatory support, patient educational programs, and preference for home-based healthcare set the path for growth in the market.
For instance, in April 2025, Insulet Corporation announced that sales of Omnipod 5 have begun in Canada. Omnipod 5 is the first tubeless, waterproof Automated Insulin Delivery (AID) System approved in Canada for use by individuals two years of age and older with type 1 diabetes.
Asia-Pacific is expected to 24.5% in the closed-loop insulin delivery systems market
The Asia-Pacific region's closed-loop insulin delivery systems market is experiencing substantial development, which is primarily due to the increasing prevalence of diabetes, particularly in countries like China, India, and Japan. The significant increase in the number of diabetics has resulted in a compelling need for advanced and efficient insulin management solutions. Government initiatives and supportive healthcare policies, such as subsidized access to insulin devices in countries such as Australia, are further driving the adoption of these systems.
Additionally, the deployment and accessibility of these inventive diabetes management tools throughout the region are being facilitated by the ongoing development of healthcare infrastructure in emerging economies.
For instance, according to the International Diabetes Federation, Japan, among the 20 IDF Western Pacific region countries, is facing a significant increase in diabetes prevalence, with an estimated 260 million people affected by the disease by 2045.
Global Closed-Loop Insulin Delivery Systems Market – Major Manufacturers
The major global players in the closed-loop insulin delivery systems market include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Bigfoot Biomedical, Roche Diabetes Care, MicroTech Medical, Medtrum Technologies, Senseonics, and EOFlow, among others.
Global Closed-Loop Insulin Delivery Systems Market - Industry Trends
- In October 2024, Luna Diabetes announced the beginning of the pivotal trial for the Luna System. Luna represents the first automated insulin delivery solution for the >90% of insulin-requiring-patients-out-there-who-insulin-pen-it, very commonly referred to as multiple daily injections (MDI). Being the first of its kind, the study will be the first ever pivotal study evaluating closed-loop technology in persons on MDI.
- Technological Innovations: Reviews ongoing clinical trials, Device Type pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Device Type Performance & Market Positioning: Analyzes Device Type performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into Device Type development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Device Type delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance Device Type safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- End-User & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Device Type
2.4. Snippet by Patient Demographics
2.5. Snippet by Control Mechanisms
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Technological Advancements in Diabetes Management
3.1.1.2. Rising Prevalence in Diabetes
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Limited Patient Awareness and Adoption
3.1.2.2. Technical Issues
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion in Emerging Markets
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established Device Type
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. South America
4.5.5. Middle East & Africa
4.6. Porter’s Five Force Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY DEVICE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
5.1.2. Market Attractiveness Index, By Device Type
5.2. Hybrid Closed-Loop Systems*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. DIY Closed-Loop Systems
6. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY PATIENT DEMOGRAPHICS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
6.1.2. Market Attractiveness Index, By Patient Demographics
6.2. Children with Type 1 Diabetes*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Adults with Type 1 Diabetes
7. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY CLOSING MECHANISM
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
7.1.2. Market Attractiveness Index, By Closing Mechanism
7.2. Bluetooth-enabled Devices*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Smartphone-Integrated Systems
8. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Homecare Settings
8.4. Specialty Diabetes Clinics
9. CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Device Type Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Medtronic*
11.1.1. Company Overview
11.1.2. Product Type Portfolio
11.1.2.1. Product Type Description
11.1.2.2. Product Type Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Device Type Sales
11.1.2.4. Device Type Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Type Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Tandem Diabetes Care
11.3. Insulet Corporation
11.4. Dexcom
11.5. Bigfoot Biomedical
11.6. Roche Diabetes Care
11.7. MicroTech Medical
11.8. Medtrum Technologies
11.9. Senseonics
11.10. EOFlow
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Device Type
2.4. Snippet by Patient Demographics
2.5. Snippet by Control Mechanisms
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Technological Advancements in Diabetes Management
3.1.1.2. Rising Prevalence in Diabetes
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Limited Patient Awareness and Adoption
3.1.2.2. Technical Issues
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion in Emerging Markets
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established Device Type
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. South America
4.5.5. Middle East & Africa
4.6. Porter’s Five Force Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY DEVICE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
5.1.2. Market Attractiveness Index, By Device Type
5.2. Hybrid Closed-Loop Systems*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. DIY Closed-Loop Systems
6. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY PATIENT DEMOGRAPHICS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
6.1.2. Market Attractiveness Index, By Patient Demographics
6.2. Children with Type 1 Diabetes*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Adults with Type 1 Diabetes
7. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY CLOSING MECHANISM
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Closing Mechanism
7.1.2. Market Attractiveness Index, By Closing Mechanism
7.2. Bluetooth-enabled Devices*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Smartphone-Integrated Systems
8. GLOBAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET, BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Homecare Settings
8.4. Specialty Diabetes Clinics
9. CLOSED-LOOP INSULIN DELIVERY SYSTEMS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Control Mechanism
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Device Type Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Medtronic*
11.1.1. Company Overview
11.1.2. Product Type Portfolio
11.1.2.1. Product Type Description
11.1.2.2. Product Type Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Device Type Sales
11.1.2.4. Device Type Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Type Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Tandem Diabetes Care
11.3. Insulet Corporation
11.4. Dexcom
11.5. Bigfoot Biomedical
11.6. Roche Diabetes Care
11.7. MicroTech Medical
11.8. Medtrum Technologies
11.9. Senseonics
11.10. EOFlow
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Closed-Loop Insulin Delivery Systems Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 8 Global Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 10 Global Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 12 Global Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Closed-Loop Insulin Delivery Systems Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Closed-Loop Insulin Delivery Systems Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 17 North America Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 18 North America Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 19 North America Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 22 South America Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 23 South America Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 24 South America Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 South America Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 27 Europe Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 28 Europe Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 29 Europe Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Europe Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Medtronic: Overview
Table 42 Medtronic: Device Type Portfolio
Table 43 Medtronic: Key Developments
Table 44 Tandem Diabetes Care: Overview
Table 45 Tandem Diabetes Care: Device Type Portfolio
Table 46 Tandem Diabetes Care: Key Developments
Table 47 Insulet Corporation: Overview
Table 48 Insulet Corporation: Device Type Portfolio
Table 49 Insulet Corporation: Key Developments
Table 50 Dexcom: Overview
Table 51 Dexcom: Device Type Portfolio
Table 52 Dexcom: Key Developments
Table 53 Bigfoot Biomedical: Overview
Table 54 Bigfoot Biomedical: Device Type Portfolio
Table 55 Bigfoot Biomedical: Key Developments
Table 56 Roche Diabetes Care: Overview
Table 57 Roche Diabetes Care: Device Type Portfolio
Table 58 Roche Diabetes Care: Key Developments
Table 59 MicroTech Medical: Overview
Table 60 MicroTech Medical: Device Type Portfolio
Table 61 MicroTech Medical: Key Developments
Table 62 Medtrum Technologies: Overview
Table 63 Medtrum Technologies: Device Type Portfolio
Table 64 Medtrum Technologies: Key Developments
Table 65: Senseonics: Overview
Table 66: Senseonics: Device Type Portfolio
Table 67: Senseonics: Key Developments
Table 68 EOFlow: Overview
Table 69 EOFlow: Device Type Portfolio
Table 70 EOFlow: Key Developments
Table 1 Global Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Closed-Loop Insulin Delivery Systems Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 8 Global Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 10 Global Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 12 Global Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Closed-Loop Insulin Delivery Systems Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Closed-Loop Insulin Delivery Systems Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 17 North America Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 18 North America Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 19 North America Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 22 South America Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 23 South America Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 24 South America Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 South America Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 27 Europe Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 28 Europe Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 29 Europe Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Europe Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Device Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Patient Demographics, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Control Mechanism, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Medtronic: Overview
Table 42 Medtronic: Device Type Portfolio
Table 43 Medtronic: Key Developments
Table 44 Tandem Diabetes Care: Overview
Table 45 Tandem Diabetes Care: Device Type Portfolio
Table 46 Tandem Diabetes Care: Key Developments
Table 47 Insulet Corporation: Overview
Table 48 Insulet Corporation: Device Type Portfolio
Table 49 Insulet Corporation: Key Developments
Table 50 Dexcom: Overview
Table 51 Dexcom: Device Type Portfolio
Table 52 Dexcom: Key Developments
Table 53 Bigfoot Biomedical: Overview
Table 54 Bigfoot Biomedical: Device Type Portfolio
Table 55 Bigfoot Biomedical: Key Developments
Table 56 Roche Diabetes Care: Overview
Table 57 Roche Diabetes Care: Device Type Portfolio
Table 58 Roche Diabetes Care: Key Developments
Table 59 MicroTech Medical: Overview
Table 60 MicroTech Medical: Device Type Portfolio
Table 61 MicroTech Medical: Key Developments
Table 62 Medtrum Technologies: Overview
Table 63 Medtrum Technologies: Device Type Portfolio
Table 64 Medtrum Technologies: Key Developments
Table 65: Senseonics: Overview
Table 66: Senseonics: Device Type Portfolio
Table 67: Senseonics: Key Developments
Table 68 EOFlow: Overview
Table 69 EOFlow: Device Type Portfolio
Table 70 EOFlow: Key Developments
LIST OF FIGURES
Figure 1 Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 3 Global Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 4 Global Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 5 Global Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Closed-Loop Insulin Delivery Systems Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Device Type, 2023-2033 (%)
Figure 8 Hybrid Closed-Loop Systems Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 9 DIY Closed-Loop Systems Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Patient Demographics, 2023-2033 (%)
Figure 11 Children with Type 1 Diabetes Patient Demographics in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 12: Adults with Type 1 Diabetes Patient Demographics in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Control Mechanism, 2023-2033 (%)
Figure 14 Bluetooth-enabled Devices Control Mechanism in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 15 Smartphone-integrated Systems Control Mechanism in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 17 Hospitals End-User in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 18 Homecare Settings End-User in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 19 Specialty Diabetes Clinics End-User in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 23 North America Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 24 North America Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 25 North America Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 26 North America Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 27 South America Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 28 South America Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 29 South America Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 30 South America Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 31 South America Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 32 South America Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 33 Europe Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 34 Europe Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 35 Europe Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 36 Europe Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 37 Europe Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Europe Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 39 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 40 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 41 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 42 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 43 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 45 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 46 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 47 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 48 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 49 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 50 Medtronic: Financials
Figure 51 Tandem Diabetes Care: Financials
Figure 52 Insulet Corporation: Financials
Figure 53 Dexcom: Financials
Figure 54 Bigfoot Biomedical: Financials
Figure 55 Roche Diabetes Care: Financials
Figure 56 MicroTech Medical: Financials
Figure 57 Medtrum Technologies: Financials
Figure 58: Senseonics: Financials
Figure 59 EOFlow: Financials
Figure 1 Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 3 Global Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 4 Global Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 5 Global Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Closed-Loop Insulin Delivery Systems Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Device Type, 2023-2033 (%)
Figure 8 Hybrid Closed-Loop Systems Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 9 DIY Closed-Loop Systems Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Patient Demographics, 2023-2033 (%)
Figure 11 Children with Type 1 Diabetes Patient Demographics in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 12: Adults with Type 1 Diabetes Patient Demographics in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Control Mechanism, 2023-2033 (%)
Figure 14 Bluetooth-enabled Devices Control Mechanism in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 15 Smartphone-integrated Systems Control Mechanism in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 17 Hospitals End-User in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 18 Homecare Settings End-User in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 19 Specialty Diabetes Clinics End-User in Global Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Closed-Loop Insulin Delivery Systems Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 23 North America Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 24 North America Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 25 North America Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 26 North America Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 27 South America Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 28 South America Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 29 South America Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 30 South America Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 31 South America Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 32 South America Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 33 Europe Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 34 Europe Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 35 Europe Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 36 Europe Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 37 Europe Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Europe Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 39 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 40 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 41 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 42 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 43 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Asia-Pacific Closed-Loop Insulin Delivery Systems Market Share, By Country, 2024 & 2033 (%)
Figure 45 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Value, 2022-2033 (US$ Billion)
Figure 46 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By Device Type, 2024 & 2033 (%)
Figure 47 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By Patient Demographics, 2024 & 2033 (%)
Figure 48 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By Control Mechanism, 2024 & 2033 (%)
Figure 49 Middle East and Africa Closed-Loop Insulin Delivery Systems Market Share, By End-User, 2024 & 2033 (%)
Figure 50 Medtronic: Financials
Figure 51 Tandem Diabetes Care: Financials
Figure 52 Insulet Corporation: Financials
Figure 53 Dexcom: Financials
Figure 54 Bigfoot Biomedical: Financials
Figure 55 Roche Diabetes Care: Financials
Figure 56 MicroTech Medical: Financials
Figure 57 Medtrum Technologies: Financials
Figure 58: Senseonics: Financials
Figure 59 EOFlow: Financials
